Whole set SNP for predicting preeclampsia and application thereof

Abstract

The invention discloses a whole set SNP for predicting preeclampsia and an application thereof. The whole set SNP provided by the invention is composed of rs7412, rs2070744, rs1800896, rs1799724, rs4762, rs2549782, rs1800629 and rs1695. The whole set SNP can be used for predicting the risk of PE of Chinese. Experiments verify that combination of the whole set SNP and combination of the whole set SNP and age for predicting the risk of PE of a to-be-detected object have a high accuracy, specificity, sensitivity and an area under the curve. The whole set SNP provided by the invention can evaluate risk of illness of the preeclampsia so as to guide intervention as soon as possible and prevention of preeclampsia, so that the morbidity of morbidity and harm to mothers and infants by preeclampsia are reduced.

Description

technical field [0001] The invention relates to a set of SNPs for predicting preeclampsia and its application in the field of biotechnology. Background technique [0002] Pre-eclampsia (PE), also known as pre-eclampsia, is a multisystem syndrome with high incidence in pregnant women. It is mainly characterized by hypertension and proteinuria after 20 weeks of pregnancy. In severe cases, cerebral ischemia, liver Complications such as renal failure, heart failure, placental abruption, hemolysis, disseminated intravascular coagulation (DIC) and postpartum hemorrhage have serious impacts on maternal health and fetal intrauterine development, and even lead to maternal and infant death. The global incidence of PE is about 2-8%. In China, with the prevalence of late marriage and late childbearing and the relaxation of family planning policies, the age of childbearing is increasing; in addition, the rapid progress of assisted reproductive technology has also led to a gradual increa...

AI Technical Summary

Problems solved by technology

[0006] Deficiencies of existing PE clinical detection methods: Although new genetic risk loci have been continuously identified, so far, clinical prediction guidance for PE (NICE, PRECOG or Chinese Medical Association Obstetrics and Gynecology Branch "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders During Pregnancy) (2015) "Revised Edition) does not include molecular genetic information; so far, although there are a small number of biomarker molecular detection methods for specific proteins or plasma metabolites, they are all aimed at the real-time diagnosis of PE that has occurred, and there is a lack of accurate diagnosis of PE. PE has not yet occurred or occurred early predictive ability

Images